secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001104659-23-029022
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics appoints Dr. Jonathan Fox to board of directors
---------------------------------------------------------------------

- Dr. Jonathan Fox appointed as Class III director, term expiring at 2024 annual meeting.
- He is President and CMO of BridgeBio Pharma and former CMO of MyoKardia, inventor of Camzyos.
- Compensation includes $38k annual cash retainer, $4k for Nominating Committee, and stock option with ~$300k grant date fair value.
- Company plans to advance EDG-7500 towards Phase 1 trial in HCM in H2 2023.
- No arrangements or transactions requiring disclosure under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465923029022/0001104659-23-029022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465923029022/tm238572d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-029022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer